Actively Recruiting
Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
Led by Lahore General Hospital · Updated on 2025-12-03
75
Participants Needed
1
Research Sites
16 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study
CONDITIONS
Official Title
Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 70 years of any gender
- Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more
- Plaque psoriasis lasting at least 6 months before the study
- Psoriasis that has not responded adequately to topical treatments
You will not qualify if you...
- Presence of other types of psoriasis or significant skin conditions that could affect psoriasis assessment
- Use of systemic corticosteroids, biologics, or other immunosuppressives within 4 weeks before the study
- Known allergies or contraindications to methotrexate or tofacitinib
- History of serious liver, kidney, blood, gastrointestinal, immune system disorders, tuberculosis, or cancer
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lahore general hospital
Lahore, Punjab Province, Pakistan
Actively Recruiting
Research Team
M
Maryam Fatima, Mbbs
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here